ArticleJournal of thoracic disease2026
Subgroup-specific predictive biomarkers in peripheral blood lymphocyte subsets for immune checkpoint inhibitor response in advanced esophageal squamous cell carcinoma: a prospective study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) significantly improve the survival of patients with advanced esophageal squamous cell carcinoma (ESCC). However, reliable biomarkers for predicting treatment response and prognosis have not yet been identified. This study investigated the relationship between specific lymphocytes in peripheral blood prior to treatment and the efficacy of ICIs, as well as prognosis, in patients with advanced ESCC. Methods: Peripheral blood samples were prospectively collected from 97 patients with stage III-IVB ESCC before ICI treatment. Flow cytometry was used to detect and quantify peripheral blood lymphocyte subsets, including natural killer (NK) cells, B cells, T cells, CD4 Results: Of the 97 patients, 42.3% (41/97) responded to ICI treatment. The baseline characteristics, including age, gender, and ICI drugs, were balanced between the response and non-response groups. The patients in the response group exhibited significantly higher baseline CD4 Conclusions: In patients with advanced ESCC, specific lymphocyte subsets in peripheral blood before treatment are closely associated with ICI efficacy and patient prognosis, and thus could potentially guide treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.